BioSpace News Archive

Marker Therapeutics, Inc. announced that the Company has entered into a Common Stock Purchase Agreement of up to $30 million with Aspire Capital Fund, LLC, a Chicago-based institutional investor and long-term Marker shareholder.

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that its chief executive officer, David Giljohann, will give a company update on Wednesday, March 4, 2020 at 11:20 AM ET at the Cowen 40th Annual Healthcare Conference in Boston.

JSR Life Sciences, LLC announced that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization and JSR Life Sciences affiliate company.

Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported fourth quarter and full year 2019 financial results and provided an operational update.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), will be featured as a presenting company during the 2020 LD Micro Virtual Investor Conference.

Daxor Corporation (NYSE MKT: DXR) disclosing its schedule of portfolio holdings as of December 31, 2019.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced it has received over 1 million Euros in 2018 CIR (French Research Tax Credit) following the successful conclusion of an audit.

Artificial intelligence and advanced visualization technology innovator TeraRecon has been awarded two first-of-its-kind technology patents from the U.S. Patent and Trademark Office.

Takeda Receives Positive CHMP -- - Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –

Masimo Announces FDA Clearance of Continuous RRp ® Monitoring